Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is an antibody-drug conjugate that targets CD30. The conjugate consists of an Anti-CD30 human-mouse chimeric IgG1 antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and results in apoptosis of tumorigenic cells. The original drug received approval from the FDA to treat adult patients with relapsed or refractory Hodgkins lymphoma and systemic anaplastic large cell lymphoma.
Biovision | A2177 | Anti-CD30 (Brentuximab Vedotin), Chimeric Antibody DataSheet
Antibody Target: CD30
Target Alternative Name: cAC10-vcMMAE, SGN 35, SGN-35, Ki-1, D1S166E, TNFRSF8
Tag Line: The biosimilar is an antibody-drug conjugate that targets CD-30, which is highly expressed on tumor cells. Upon detachment from the antibody inside the cell, the drug disrupts the microtubule network, which leads to cell cycle arrest, and apoptosis of malignant cells
Category: Biosimilars
Host: Human/Mouse chimeric
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human CD30
Accession #: DB08870
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
